PepGen
2 followers
Driven by its proprietary Enhanced Delivery Oligonucleotide (EDO) platform, PepGen is creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic diseases, with an initial focus on neuromuscular diseases.
Org chart
James McArthur
President & CEO
James McArthur
Collapse
Jaya Goyal
EVP, Research & Preclinical Development
Niels Svenstrup
SVP, Chemistry, Manufacturing & Controls
Michelle Mellion
SVP & Head, Clinical Development
Jeffrey Foy
VP, Toxicology
Debra Sawyer
VP, Quality Assurance
Jane Larkindale
VP, Clinical Science
Hayley Parker
VP, Global Regulatory Affairs
